| Name | Title | Contact Details |
|---|
Merck Frosst Canada is a Kirkland, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genius Therapy LLC is an early intervention agency that was founded to promote and enhance the development of infants and young children with special needs between the ages of birth to three. Our mission is for all children with special needs to achieve their maximum personal development both as individuals and as learners. At Genius Therapy, we develop programs designed specifically for each child, utilizing the principles of special instruction, applied behavioral analysis, occupational therapy and speech and language therapy.
Pharmacyclics, an AbbVie company, is a biopharmaceutical company located in Sunnyvale, CA employing more than 900 people. We focus on developing and commercializing innovative small-molecule therapies for the treatment of certain cancers and immune-mediated diseases.
Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns` programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. Terns` investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.